New data from the REPRISE trial confirms that tolvaptan slows the progression of autosomal dominant polycystic disease (ADPKD). Although not yet approved by the United States Food and Drug administration, tolvaptan is now likely to become standard care for early and later stages of ADPKD in Europe and in various countries worldwide.
Refers to Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med.377, 1930-1942 (2017)